Generic drug sponsors may not see the US Food and Drug Administration employ its imminent action authority often to deal with last-minute reference product labeling changes that are intended to delay competition from entering the market.
Other agency policies, along with a new commitment in the upcoming generic drug user fee reauthorization, likely will be more suited to dealing with the problem, said Molly Ventrelli,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?